Trial Profile
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs IO 102 (Primary) ; IO-103 (Primary) ; Nivolumab (Primary) ; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions
- 26 Jan 2023 Status changed from recruiting to discontinued.
- 09 Nov 2022 According to an IO Biotech media release, data from this trial are being presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022).
- 05 Oct 2022 According to an IO Biotech media release, update on this study will be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022).